Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. The firm produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The firm operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).
How did ASND's recent EPS compare to expectations?
The most recent EPS for Ascendis Pharma A/S is $-0.55, beating expectations of $-0.04.
How did Ascendis Pharma A/S ASND's revenue perform in the last quarter?
Ascendis Pharma A/S revenue for the last quarter is $-0.55
What is the revenue estimate for Ascendis Pharma A/S?
According to 14 of Wall street analyst, the revenue estimate of Ascendis Pharma A/S range from $330.02M to $265.47M
What's the earning quality score for Ascendis Pharma A/S?
Ascendis Pharma A/S has a earning quality score of B+/52.414875. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Ascendis Pharma A/S report earnings?
Ascendis Pharma A/S next earnings report is expected in 2026-05-12
What are Ascendis Pharma A/S's expected earnings?
Ascendis Pharma A/S expected earnings is $251.23M, according to wall-street analysts.
Did Ascendis Pharma A/S beat earnings expectations?
Ascendis Pharma A/S recent earnings of $247.5M does not beat expectations.